IL149264A0 - Use of adatanserin for the treatment of neurodegenerative conditions - Google Patents
Use of adatanserin for the treatment of neurodegenerative conditionsInfo
- Publication number
- IL149264A0 IL149264A0 IL14926400A IL14926400A IL149264A0 IL 149264 A0 IL149264 A0 IL 149264A0 IL 14926400 A IL14926400 A IL 14926400A IL 14926400 A IL14926400 A IL 14926400A IL 149264 A0 IL149264 A0 IL 149264A0
- Authority
- IL
- Israel
- Prior art keywords
- adatanserin
- treatment
- neurodegenerative conditions
- treating
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processing Of Meat And Fish (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43921999A | 1999-11-12 | 1999-11-12 | |
PCT/US2000/030973 WO2001034136A2 (en) | 1999-11-12 | 2000-11-10 | Use of adatanserin for the treatment of neurodegenerative conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149264A0 true IL149264A0 (en) | 2002-11-10 |
Family
ID=23743796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14926400A IL149264A0 (en) | 1999-11-12 | 2000-11-10 | Use of adatanserin for the treatment of neurodegenerative conditions |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1242089B1 (xx) |
JP (1) | JP2003513915A (xx) |
KR (1) | KR100757226B1 (xx) |
CN (1) | CN100469368C (xx) |
AT (1) | ATE291919T1 (xx) |
AU (1) | AU773733B2 (xx) |
BR (1) | BR0015523A (xx) |
CA (1) | CA2390797A1 (xx) |
CZ (1) | CZ298535B6 (xx) |
DE (1) | DE60019166T2 (xx) |
EA (1) | EA006099B1 (xx) |
ES (1) | ES2235998T3 (xx) |
HK (1) | HK1046505B (xx) |
HU (1) | HUP0301847A3 (xx) |
IL (1) | IL149264A0 (xx) |
MX (1) | MXPA02004654A (xx) |
NO (1) | NO322371B1 (xx) |
NZ (1) | NZ518814A (xx) |
PL (1) | PL355014A1 (xx) |
PT (1) | PT1242089E (xx) |
WO (1) | WO2001034136A2 (xx) |
ZA (1) | ZA200204682B (xx) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2235998T3 (es) * | 1999-11-12 | 2005-07-16 | Wyeth | Utilizacion de adatanserina para el tratamiento de los trastornos degenerativos agudos. |
WO2009082268A2 (ru) | 2007-12-21 | 2009-07-02 | Alla Chem, Llc | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5441961A (en) * | 1992-08-27 | 1995-08-15 | Eli Lilly And Company | Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines |
US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
US5902815A (en) * | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
ES2235998T3 (es) * | 1999-11-12 | 2005-07-16 | Wyeth | Utilizacion de adatanserina para el tratamiento de los trastornos degenerativos agudos. |
-
2000
- 2000-11-10 ES ES00979157T patent/ES2235998T3/es not_active Expired - Lifetime
- 2000-11-10 BR BR0015523-3A patent/BR0015523A/pt not_active Application Discontinuation
- 2000-11-10 AT AT00979157T patent/ATE291919T1/de not_active IP Right Cessation
- 2000-11-10 HU HU0301847A patent/HUP0301847A3/hu unknown
- 2000-11-10 CZ CZ20021629A patent/CZ298535B6/cs not_active IP Right Cessation
- 2000-11-10 CA CA002390797A patent/CA2390797A1/en not_active Abandoned
- 2000-11-10 JP JP2001536136A patent/JP2003513915A/ja not_active Withdrawn
- 2000-11-10 PL PL00355014A patent/PL355014A1/xx not_active IP Right Cessation
- 2000-11-10 EP EP00979157A patent/EP1242089B1/en not_active Expired - Lifetime
- 2000-11-10 WO PCT/US2000/030973 patent/WO2001034136A2/en active IP Right Grant
- 2000-11-10 EA EA200200559A patent/EA006099B1/ru not_active IP Right Cessation
- 2000-11-10 KR KR1020027006067A patent/KR100757226B1/ko not_active IP Right Cessation
- 2000-11-10 MX MXPA02004654A patent/MXPA02004654A/es active IP Right Grant
- 2000-11-10 NZ NZ518814A patent/NZ518814A/en unknown
- 2000-11-10 DE DE60019166T patent/DE60019166T2/de not_active Expired - Fee Related
- 2000-11-10 PT PT00979157T patent/PT1242089E/pt unknown
- 2000-11-10 IL IL14926400A patent/IL149264A0/xx unknown
- 2000-11-10 AU AU16567/01A patent/AU773733B2/en not_active Ceased
- 2000-11-10 EP EP05001510A patent/EP1547597A3/en not_active Withdrawn
- 2000-11-10 CN CNB008156085A patent/CN100469368C/zh not_active Expired - Fee Related
-
2002
- 2002-05-07 NO NO20022187A patent/NO322371B1/no not_active IP Right Cessation
- 2002-06-11 ZA ZA200204682A patent/ZA200204682B/en unknown
- 2002-11-08 HK HK02108123.1A patent/HK1046505B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0713701T3 (da) | 2-Brommelatonin til behandling af søvnforstyrrelser | |
SG52443A1 (en) | Methods and compositions for the treatment of disease with interferon while reducing sid effects | |
HU913447D0 (en) | Medical preparations and their use in treating neurologic disorders | |
EA200300046A1 (ru) | Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию | |
IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
HUP0100437A2 (hu) | Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására | |
FI19991893A (fi) | Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö | |
IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
BG106171A (en) | Compositions and uses of et743 for treating cancer | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
DK0501705T3 (da) | Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje | |
FR2712811B1 (fr) | Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet. | |
IL130785A0 (en) | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same | |
EP1006793A4 (en) | COMPOSITIONS FOR TREATING ARRHYTHMIA AND METHODS OF TREATMENT | |
JP2003514025A5 (xx) | ||
IL149264A0 (en) | Use of adatanserin for the treatment of neurodegenerative conditions | |
FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles | |
FR2818147B1 (fr) | Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine | |
Scali et al. | Analgesic effect of ipriflavone versus sCalcitonin in the treatment of osteoporotic vertebral pain. | |
RU94013606A (ru) | Гемостимулятор | |
黄圣源 et al. | CLINICAL OBSERVATION ON TREATMENT OF DISORDERS OF THE OPTIC NERVE BY ACUPUNCTURE | |
Garmash et al. | Use of phthivazide in the treatment of patients with acute pneumonia and chronic bronchitis | |
EE04951B1 (et) | R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine unehirete raviks | |
WO2003059334A3 (en) | Gemcitabine in the treatment of smallpox |